BIOMAT Database Logo BIOMAT Database Logo

Reversal of allograft rejection using the monoclonal antibody, Campath-1G. 1991

P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Department of Surgery, University of Cambridge, Addenbrooke's Hospital, England.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D000074301 CD52 Antigen A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB). CD52 Protein,CDw52 Antigen,Cambridge Pathology 1 Antigen,Campath-1 Antigen,Campath-1 Receptor,Campath-1H Antigen,HLA-Bw52,HLA-Bw52 Antigen,Lymphocyte Antigen CD52,Lymphocyte Antigen CDw52,CD52, Lymphocyte Antigen,CDw52, Lymphocyte Antigen,Campath 1 Antigen,Campath 1 Receptor,Campath 1H Antigen,HLA Bw52,HLA Bw52 Antigen
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation

Related Publications

P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Campath-1G. Campath IgG, Campath-1-IgG antibody.
January 1999, Drugs in R&D,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Successful reversal of acute cardiac allograft rejection with OKT*3 monoclonal antibody.
November 1987, Circulation,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Monoclonal antibody for reversal of acute renal allograft rejection in pediatric patients.
November 1985, Transplantation,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.
January 1986, Progress in clinical and biological research,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
January 2000, Cytotherapy,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Prevention and reversal of renal allograft rejection by monoclonal antibody to CD45RB in the mouse model.
February 1995, Transplantation proceedings,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Reversal of acute allograft rejection using immunotoxin.
August 1998, Transplantation proceedings,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Reversal of transplant rejection by monoclonal antiblast antibody.
November 1983, Lancet (London, England),
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Reversal of allograft rejection.
May 1994, The Annals of thoracic surgery,
P J Friend, and H Waldmann, and G Hale, and S Cobbold, and P Rebello, and S Thiru, and N V Jamieson, and P S Johnston, and R Y Calne
Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
April 1987, Transplantation proceedings,
Copied contents to your clipboard!